AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue growth, yet face ...

Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for ...

The Phase III TRIDENT study failed to show statistical significance in OS when Optune Gio was used earlier.

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Christoph Brackmann ...

Amgen posts strong profits and cash flow, while NovoCure pursues growth with a direct-to-patient cancer therapy model and ...

NovoCure (NVCR) drew investor attention after releasing topline Phase 3 TRIDENT data, showing that starting Tumor Treating ...

Novocure (NVCR) stock plunges as the company annouces a late-stage trial setback for its cancer treatment device, Tumor ...

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of ...

Novocure’ s shares stumbled nearly 20% after the company disclosed it failed to meet its primary endpoints in the TRIDENT ...

In a press release Wednesday, Novocure announced that its phase 3 METIS clinical trial met its primary endpoint by "demonstrating a statstically significant improvement in time to ...

Novocure stock slumped Thursday after the company's wearable medical device failed in patients with a form of brain cancer.

Novocure (NASDAQ: NVCR) announced topline results today from its Phase 3 TRIDENT trial, which evaluated the initiation of Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma (GBM ...